AMPLATZER Cardiac Plug Clinical Trial

Inclusion Criteria:

• Subject must have a documented history of paroxysmal, persistent or permanentnonvalvular atrial fibrillation

• Subject must be ≥18 years of age

• Subject must be on warfarin or dabigatran therapy

• Subject must be eligible for long term warfarin or dabigatran therapy

• Subject must have a CHADS(2) score of 2 or greater

Summary of Exclusion Criteria:

• Subject who requires warfarin or dabigatran for a condition other than AF

• Subject who is on clopidogrel or another P2Y12 platelet inhibitor such as prasugrel orticagrelor

• Subject who has an absolute or relative contraindication to aspirin, or warfarin anddabigatran

• Subject with a New York Heart Association (NYHA) classification equal to IV

• Subject with an implanted or surgical repair atrial septal defect (ASD) device orpatent foramen ovale (PFO) device

• Subject with aortic or mitral valve regurgitation of grade 2+ or greater

• Subject with left ventricular ejection fraction (LVEF) ≤30

• Subject with mitral or aortic prosthetic valve

• Subject with a history of hemorrhagic or aneurysmal stroke

• Subject with a history of previous radio frequency (RF) ablation for atrialfibrillation

• Subject with a body mass index (BMI) ≥40

• Subject with a history of acute or recent MI, or unstable angina, or coronary arterybypass graft surgery (within 6 months)

• Subject who is on aspirin dose therapy greater than 81mg/day at time of enrollment